Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v2-FR
Language French French
Date Updated 2022-09-22 2022-09-22
Drug Identification Number 02438712 02438712
Brand name EGRIFTA EGRIFTA
Common or Proper name Tesamorelin for injection Tesamorelin for injection
Company Name THERATECHNOLOGIES INC THERATECHNOLOGIES INC
Ingredients TESAMORELIN TESAMORELIN
Strength(s) 1MG 1MG
Dosage form(s) POWDER FOR SOLUTION KIT POWDER FOR SOLUTION KIT
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 60 vials containing (each) 1 mg of tesamorelin 60 vials containing (each) 1 mg of tesamorelin
ATC code H01AC H01AC
ATC description ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2022-09-30 2022-09-30
Actual discontinuation date
Remaining supply date 2022-09-30 2022-09-30
Discontinuation status To be discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments
Health Canada comments